The latest new contracts, like LIfT BioSciences’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
LIfT BioSciences partners with University of Galway for clinical trial in Ireland
Apr 28, 2025•about 1 year ago
Contract Type
partnership
LondonBiotechnologyHealth CareTherapeutics
Description
LIfT BioSciences has announced a strategic partnership with the University of Galway to conduct a planned clinical trial for their Immunomodulatory Alpha Neutrophils (IMANs) in Ireland. The partnership aims to combine expertise in immunotherapy, oncology, patient care, and advanced manufacturing to enhance LIfT’s clinical-stage research capabilities and accelerate the pathway to delivering IMANs to patients.
Company Information
Company
LIfT BioSciences
Location
London, England, United Kingdom
About
LIfT Biosciences is a biotech bringing to market a first-in-class alpha neutrophil cell therapy that overcomes the limitations of current therapies in solid tumours by destroying tumours both directly and indirectly. LIfT’s Immunomodulatory Alpha Neutrophils (IMANs) turn the tumour microenvironment against the tumour as they recruit the rest of the immune system to destroy the tumour to give a durable response and lasting immunity. The patented breakthrough N-LIfT platform is produced from a patented process using exceptional stem cells (iPSC or HSC), a proprietary enhancement media and genetic engineering (e.g. CARs). The resulting CAR-IMAN cells give cancer patients potentially hundreds of times the cancer killing ability they naturally possess.
LondonBiotechnologyHealth CareTherapeutics